We are live on ! Find out more

211 hedge funds and large institutions have $1.58B invested in Genmab in 2021 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 67 increasing their positions, 84 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 28

1% more call options, than puts

Call options by funds: $292K | Put options by funds: $288K

0% more funds holding

Funds holding: 211211 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

4.58% less ownership

Funds ownership: 65.11%60.53% (-4.6%)

17% less capital invested

Capital invested by funds: $1.89B → $1.58B (-$314M)

20% less repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 84

Holders
211
Holders Change
Holders Change %
0%
% of All Funds
3.25%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
31
Increased
67
Reduced
84
Closed
28
Calls
$292K
Puts
$288K
Net Calls
+$4K
Net Calls Change
-$6M

GMAB Hedge Fund Activity: Q4 2021 in Review

211 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q4 2021, worth a combined $1.58B — down 17% from $1.89B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new GMAB positions and 28 closed out — a net gain of 3 holders — while 67 added to existing stakes and 84 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $7.32M. The largest seller was BlackRock, cutting an estimated $60.3M.

  • 211 institutional investors held Genmab (GMAB) as of Q4 2021, unchanged from Q3 2021.
  • Funds reported $1.58B of Genmab stock for Q4 2021, down 17% quarter-over-quarter.
  • 31 funds opened new Genmab positions in Q4 2021 and 28 closed out, a net change of +3 holders.
  • The largest Genmab buyer in Q4 2021 was Renaissance Technologies, an estimated $7.32M added.
  • The largest Genmab seller in Q4 2021 was BlackRock, an estimated $60.3M sold.

Based on aggregated 13F filings for Q4 2021.